Get started
Author

Tsubasa Nagasaki

ORCID: 0009-0006-8098-1508
Observed ORCID: 0009-0006-8098-1508
OpenAlex ID: A5065834529
Supplementary Figure S2 from ZSTK3744, a Novel Aryl Hydrocarbon Receptor Agonist, Exhibits Efficacy against Chemotherapy-Resistant Triple-Negative Breast Cancer
2026 · Takahiro Ohashi, Tsubasa Nagasaki, et al.
Supplementary Figure S3 from ZSTK3744, a Novel Aryl Hydrocarbon Receptor Agonist, Exhibits Efficacy against Chemotherapy-Resistant Triple-Negative Breast Cancer
2026 · Takahiro Ohashi, Tsubasa Nagasaki, et al.
Supplementary Table S2 from ZSTK3744, a Novel Aryl Hydrocarbon Receptor Agonist, Exhibits Efficacy against Chemotherapy-Resistant Triple-Negative Breast Cancer
2026 · Takahiro Ohashi, Tsubasa Nagasaki, et al.
Supplementary Figure S6 from ZSTK3744, a Novel Aryl Hydrocarbon Receptor Agonist, Exhibits Efficacy against Chemotherapy-Resistant Triple-Negative Breast Cancer
2026 · Takahiro Ohashi, Tsubasa Nagasaki, et al.
Supplementary Figure S4 from ZSTK3744, a Novel Aryl Hydrocarbon Receptor Agonist, Exhibits Efficacy against Chemotherapy-Resistant Triple-Negative Breast Cancer
2026 · Takahiro Ohashi, Tsubasa Nagasaki, et al.
Supplementary Table S1 from ZSTK3744, a Novel Aryl Hydrocarbon Receptor Agonist, Exhibits Efficacy against Chemotherapy-Resistant Triple-Negative Breast Cancer
2026 · Takahiro Ohashi, Tsubasa Nagasaki, et al.
Supplementary Figure S7 from ZSTK3744, a Novel Aryl Hydrocarbon Receptor Agonist, Exhibits Efficacy against Chemotherapy-Resistant Triple-Negative Breast Cancer
2026 · Takahiro Ohashi, Tsubasa Nagasaki, et al.
Supplementary Figure S1 from ZSTK3744, a Novel Aryl Hydrocarbon Receptor Agonist, Exhibits Efficacy against Chemotherapy-Resistant Triple-Negative Breast Cancer
2026 · Takahiro Ohashi, Tsubasa Nagasaki, et al.
Supplementary Figure S5 from ZSTK3744, a Novel Aryl Hydrocarbon Receptor Agonist, Exhibits Efficacy against Chemotherapy-Resistant Triple-Negative Breast Cancer
2026 · Takahiro Ohashi, Tsubasa Nagasaki, et al.
Data from ZSTK3744, a Novel Aryl Hydrocarbon Receptor Agonist, Exhibits Efficacy against Chemotherapy-Resistant Triple-Negative Breast Cancer
2026 · Takahiro Ohashi, Tsubasa Nagasaki, et al.
Table 1 from ZSTK3744, a Novel Aryl Hydrocarbon Receptor Agonist, Exhibits Efficacy against Chemotherapy-Resistant Triple-Negative Breast Cancer
2026 · Takahiro Ohashi, Tsubasa Nagasaki, et al.
Supplementary Table S2 from ZSTK3744, a Novel Aryl Hydrocarbon Receptor Agonist, Exhibits Efficacy against Chemotherapy-Resistant Triple-Negative Breast Cancer
2026 · Takahiro Ohashi, Tsubasa Nagasaki, et al.
Supplementary Figure S2 from ZSTK3744, a Novel Aryl Hydrocarbon Receptor Agonist, Exhibits Efficacy against Chemotherapy-Resistant Triple-Negative Breast Cancer
2026 · Takahiro Ohashi, Tsubasa Nagasaki, et al.
Figure 4 from ZSTK3744, a Novel Aryl Hydrocarbon Receptor Agonist, Exhibits Efficacy against Chemotherapy-Resistant Triple-Negative Breast Cancer
2026 · Takahiro Ohashi, Tsubasa Nagasaki, et al.
Table 2 from ZSTK3744, a Novel Aryl Hydrocarbon Receptor Agonist, Exhibits Efficacy against Chemotherapy-Resistant Triple-Negative Breast Cancer
2026 · Takahiro Ohashi, Tsubasa Nagasaki, et al.
Supplementary Figure S3 from ZSTK3744, a Novel Aryl Hydrocarbon Receptor Agonist, Exhibits Efficacy against Chemotherapy-Resistant Triple-Negative Breast Cancer
2026 · Takahiro Ohashi, Tsubasa Nagasaki, et al.
Supplementary Figure S7 from ZSTK3744, a Novel Aryl Hydrocarbon Receptor Agonist, Exhibits Efficacy against Chemotherapy-Resistant Triple-Negative Breast Cancer
2026 · Takahiro Ohashi, Tsubasa Nagasaki, et al.
Figure 3 from ZSTK3744, a Novel Aryl Hydrocarbon Receptor Agonist, Exhibits Efficacy against Chemotherapy-Resistant Triple-Negative Breast Cancer
2026 · Takahiro Ohashi, Tsubasa Nagasaki, et al.
Figure 5 from ZSTK3744, a Novel Aryl Hydrocarbon Receptor Agonist, Exhibits Efficacy against Chemotherapy-Resistant Triple-Negative Breast Cancer
2026 · Takahiro Ohashi, Tsubasa Nagasaki, et al.
Supplementary Table S1 from ZSTK3744, a Novel Aryl Hydrocarbon Receptor Agonist, Exhibits Efficacy against Chemotherapy-Resistant Triple-Negative Breast Cancer
2026 · Takahiro Ohashi, Tsubasa Nagasaki, et al.
Supplementary Figure S4 from ZSTK3744, a Novel Aryl Hydrocarbon Receptor Agonist, Exhibits Efficacy against Chemotherapy-Resistant Triple-Negative Breast Cancer
2026 · Takahiro Ohashi, Tsubasa Nagasaki, et al.
Supplementary Figure S1 from ZSTK3744, a Novel Aryl Hydrocarbon Receptor Agonist, Exhibits Efficacy against Chemotherapy-Resistant Triple-Negative Breast Cancer
2026 · Takahiro Ohashi, Tsubasa Nagasaki, et al.
Figure 2 from ZSTK3744, a Novel Aryl Hydrocarbon Receptor Agonist, Exhibits Efficacy against Chemotherapy-Resistant Triple-Negative Breast Cancer
2026 · Takahiro Ohashi, Tsubasa Nagasaki, et al.
Supplementary Figure S5 from ZSTK3744, a Novel Aryl Hydrocarbon Receptor Agonist, Exhibits Efficacy against Chemotherapy-Resistant Triple-Negative Breast Cancer
2026 · Takahiro Ohashi, Tsubasa Nagasaki, et al.
Figure 6 from ZSTK3744, a Novel Aryl Hydrocarbon Receptor Agonist, Exhibits Efficacy against Chemotherapy-Resistant Triple-Negative Breast Cancer
2026 · Takahiro Ohashi, Tsubasa Nagasaki, et al.
Works count: 29
Citation count:
H-index:
I10-index:
Year
Topic
Type